DCM
RNAM

Dupont Capital Management’s Avidity Biosciences RNAM Stock Holding History

Dupont Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-10,029
Closed -$256K – 1644
2020
Q4 		$256K Sell
10,029
-749
-7% -$21.8K 0.01% 1087
2020
Q3 		$303K Buy
+10,778
New +$311K 0.01% 969

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dupont Capital Management's RNAM Position: Q1 2021 in Review

Dupont Capital Management sold out of Avidity Biosciences (RNAM) in Q1 2021, closing a stake of 10,029 shares — an estimated $256K sold.

Dupont Capital Management first reported a position in RNAM in Q3 2020 and held it in 2 quarters. The position peaked at $303K in Q3 2020. 100 funds tracked by Wall St. Rank hold RNAM as of Q1 2021.

  • Dupont Capital Management reported no remaining Avidity Biosciences position as of Q1 2021 after selling out during the quarter.
  • Dupont Capital Management sold 10,029 Avidity Biosciences shares in Q1 2021, an estimated $256K.
  • Dupont Capital Management first reported a position in Avidity Biosciences in Q3 2020 and held it in 2 quarters.
  • Dupont Capital Management's Avidity Biosciences position peaked at $303K in Q3 2020.
  • 100 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2021.

Based on Dupont Capital Management's 13F filing for Q1 2021, filed 29 Apr 2021.